MOTS-c by prescription in the US

MOTS-c is a short chain of 16 amino acids, the building blocks of protein. Your cells make it inside their mitochondria, the parts of the cell that turn food into energy. Scientists first described it in 2015. The MOTS-c sold for treatment is made in a lab.

The name is short for mitochondrial open reading frame of the 12S rRNA-c. You may also see it written as MOTSc or MOTs-C, or called a mitochondrial-derived peptide. The form named in the HHS policy is MOTS-c acetate.

It is not FDA approved for any use, and no approved medicine contains it. The FDA found that European regulators have not authorized any product with it either.

Online, it is promoted for weight loss, blood sugar control, energy, exercise performance and slower aging. Those claims rest on studies in mice and cells, as the evidence section below explains.

Compounding is when a licensed pharmacy makes a drug for one patient on a prescription. Under federal law, a 503A pharmacy can usually only use ingredients that pass one of three tests. The ingredient is part of a drug the FDA has approved, has a USP monograph, or is on the FDA's 503A bulks list. MOTS-c passes none of them.

From September 29, 2023, to April 22, 2026, the FDA kept MOTS-c on its Category 2 list. That list flags ingredients that may pose serious safety risks. MOTS-c came off it after the groups that nominated it withdrew. HHS says neither step changed its legal status.

In July 2026, the FDA's compounding advisory committee voted in favor of adding MOTS-c to the 503A bulks list. According to PharmExec, a trade journal, the vote was 7 to 5, with two abstentions. FDA staff had advised against it. They cited missing quality data and no human studies. The vote is advice only, and the FDA has not made a final decision.

On October 30, 2026, HHS published a notice in the Federal Register, FR Doc 2026-22192. HHS Secretary Robert F. Kennedy, Jr. signed it. The notice itself names no peptides. The policy it announces lists six in its Appendix A, and MOTS-c is one of them.

HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed doctor that compounds MOTS-c under the policy's conditions. This lasts until a final FDA rule decides whether MOTS-c goes on the 503A bulks list.

This is not FDA approval and it is not a final rule. The notice calls the policy a draft and takes public comments for two weeks. HHS says the policy is not binding and may be revisited if a safety or quality problem appears.

The pharmacy needs a valid prescription for you by name. It cannot sell MOTS-c to anyone without one.

For MOTS-c, the policy covers only shots under the skin or into a muscle. It names the acetate salt form. Capsules, nasal sprays, creams and IV drips are not covered for MOTS-c.

Each product may contain only one active ingredient. Blends that mix MOTS-c with other peptides or vitamins fall outside the policy. If a device comes in the pack, it must be an FDA-cleared syringe.

The raw peptide must come from a maker registered with the FDA. Each lot needs a certificate of analysis. It must show tests for identity, purity, strength and contaminants such as endotoxins and heavy metals.

The label must say: "This is a compounded drug product. Not for resale." The pharmacy must report serious side effects and quality problems to the FDA through MedWatch.

Start with a visit, in person or by video, with a licensed prescriber. They should review your health history, your current medicines and why you want MOTS-c. They decide whether a prescription is right for you.

The prescriber must be licensed in the state where you are at the time of the visit. Most state medical boards say this, and some states add their own telehealth rules. Ask which states they are licensed in before you book.

The prescription then goes to a state-licensed 503A compounding pharmacy. The pharmacy makes the product for you and ships it or has it ready to pick up. Not every pharmacy ships to every state, so ask before you pay.

In a proper prescription route, a prescriber approves you before you can check out for the peptide. A site that sells MOTS-c with no prescription, or as "research use only", is not using this route.

Almost all research on MOTS-c has been done in mice, rats and cells. In mice, it prevented weight gain and insulin resistance on a high-fat diet. It also improved physical performance in young and old mice. Animal results do not show that it works in people.

Most studies in people only measure the MOTS-c the body already makes. For example, levels in muscle and blood rise after exercise. Those studies did not give MOTS-c as a treatment.

The FDA's 2026 review found no published study that gave MOTS-c to people by any route. It said there was not enough evidence to judge it for obesity or osteoporosis. It also noted a lab study in which MOTS-c broke down quickly in human blood. So it is not clear that a shot reaches useful levels in the body.

One early trial tested a modified version of MOTS-c, called CB4211, in 88 people. HHS says that trial reported no serious side effects. Its results are not posted on ClinicalTrials.gov, and its development was stopped.

A placebo-controlled trial of MOTS-c itself began in China in 2026. It is for adults with prediabetes and overweight. Results are not expected before 2027.

There are treatments the FDA has approved for obesity and for osteoporosis. The FDA pointed this out in its review. If those are your goals, ask your prescriber about them.

The FDA says the safety risks of MOTS-c in people are unknown. It found no animal studies of harm from repeated use, damage to genes, cancer risk or effects on pregnancy.

A key FDA concern is immune reactions to injected peptides. Peptides can clump, and impurities from manufacturing can add risk. The FDA says immune reactions to peptides can range from no symptoms to life-threatening.

The FDA found no side effect reports for MOTS-c in its database, in searches up to March 2025. That does not show it is safe. Until now, 503A pharmacies generally did not report side effects to the FDA. Under the new policy, they must report serious ones.

Ask your prescriber: Which states are you licensed in? What is the evidence for my goal, and is there an approved option? What side effects should I watch for, and who do I contact if I have one? Is it safe with my other medicines, or if I am pregnant or have had cancer?

Ask the pharmacy: What is your name, and are you a 503A pharmacy licensed in my state? Who made the raw peptide, and is that maker registered with the FDA? Can I see the certificate of analysis for my lot, including endotoxin and sterility tests? Is MOTS-c the only active ingredient?

If you have a side effect, tell your prescriber. You can also report it to the FDA through MedWatch.

We checked 250 US sellers across the six peptides in the HHS policy. 73 ranked providers list MOTS-c. What they charge: $165 to $275 a month, for the 4 of 8 that post a price and sell by the month. We never mix a monthly price with a price per vial. Check what each price covers. Another 14 list it but are not ranked, each with the reason on this page.

We also found 5 sellers offering MOTS-c with no real prescription check, often as "research use only". We do not rank them or name them here.

Legal checks carry the most weight in our scores. We look for a state license, a prescription before checkout, single-ingredient products, injection forms the policy covers, and any FDA warning letters. Quality checks include a named, FDA-registered ingredient maker and batch certificates of analysis. We also check whether prices and the states served are public.

Prices and fees change often. Check them, and the states served, on the provider's own page before you book a visit. The research for this page was done on October 29, 2026.